Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
(NASDAQ: MIRM) Delayed: 111.07 +3.30 (3.06%)
Previous Close $107.77    52 Week High $ 
Open $105.48    52 Week Low $ 
Day High $111.36    P/E N/A 
Day Low $105.18    EPS $ 
Volume 1,129,074